Alicyn is the Global Head of Patient Centered Outcomes Research for Oncology at Genentech, a role she has held since 2012. She has over nine years of experience developing and implementing innovative PRO strategies and endpoints across tumor types within oncology drug development (e.g. non-small cell lung cancer, head and neck cancer, hematological malignancies, gastric cancer, glioblastoma, ovarian cancer, hepatocellular carcinoma, breast cancer [from neo-adjuvant to metastatic], renal cell carcinoma, and pancreatic cancer). Her current research includes: assessment of symptom burden in lung cancer, comparative tolerability assessment, and the development of new tools for neurocognitive assessment of brain metastases, as well as the CNS effects of treatment. Alicyn currently is co-chair of the C-Path NSCLC Working Group. Prior to joining Genentech Alicyn was a Director in Health Economics and Outcomes Research at Pfizer Oncology for six years, where she was responsible for Outcomes Research strategy for the development pipeline, including PRO endpoints. Additionally, Alicyn spearheaded and lead a company-wide initiative to develop integrated treatment management guidelines for common toxicities across small molecules, as well as designed a novel treatment management intervention trial using PROs as primary endpoint of efficacy. She completed her Masters of Public Health from the University of Connecticut School of Medicine with concentrations in Epidemiology and Outcomes Research. Alicyn is passionate about measuring the impact of cancer and its treatment on patients in a rigorous and reliable way to provide patients with the best evidence to make one of the most important healthcare decisions they will face in their life time: choice of treatment following a cancer diagnosis.
Digital Health and Clinical Trials: How Sensors and Clinical Devices are Driving Superior Outcomes (Luncheon Session)